Market News & Trends
WACKER, CordenPharma, LMU & HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma International GmbH have launched a…
Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 & Atezolizumab in Hepatocellular Carcinoma
Omega Therapeutics, Inc. recently announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular…
SCYNEXIS & GSK Announce Exclusive Agreement to Commercialize & Further Develop Novel, First-in-Class Medicine to Treat Fungal Infection
SCYNEXIS, Inc. GSK plc recently announced they have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the….
PDS Biotech Announces Plan to Initiate Phase 3 Study
PDS Biotechnology Corporation recently announced it has completed key tech transfer, scale up, and manufacturing activities required to initiate a global, multicenter Phase 3 registrational…
Immutep Announces Expansion of Triple Combination Therapy in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha (efti), a soluble LAG-3 protein…
Lonza Completes Clinical & Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza recently announced the completion of its planned cGMP clinical and commercial drug product manufacturing line in Visp (CH). The new line will support customers…
Corcept Therapeutics Initiates CATALYST Clinical Trial
Corcept Therapeutics Incorporated recently announced it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control…
Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs
Catalent recently announced the launch of the ProteoSuite Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into….
Cardiff Oncology Announces First Patient Dosed in Phase 2 Trial of Onvansertib in Patients With Metastatic Colorectal Cancer
Cardiff Oncology, Inc. recently announced the first patient was dosed this month with its investigational drug onvansertib in its Phase 2 ONSEMBLE trial (NCT05593328). The…
Caribou Biosciences Initiates Dose Expansion Portion of Phase 1 Trial in Second-Line LBCL Patients
Caribou Biosciences, Inc. recently announced initiation of the dose expansion portion of the CB-010 ANTLER Phase 1 trial in second-line patients with large B cell…
Vetter Performs Extraordinarily With Six Wins in the 12th Annual CDMO Leadership Awards
Vetter recently earned the esteemed 2023 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service. In addition, the…
Tiziana Life Sciences to Proceed With Phase 2 Clinical Trial in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences Ltd. recently announced it has received feedback based on the US FDA Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS…..
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Revive Therapeutics Ltd. recently provided an update on the company’s Phase 1/2 clinical study (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a…
Covant & Boehringer Ingelheim Collaborate to Develop Novel ADAR1 Inhibitor for Use in Cancer Patients
Covant Therapeutics has recently entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim….
Acumen Pharmaceuticals Presents In Vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. has recently demonstrated the utility of a human in vitro model of iPSC-derived excitatory neurons for a better understanding of which forms…
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People With Chronic Hepatitis B
Vaccitech plc recently announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300 in people with chronic Hepatitis…
Cyclerion Therapeutics Receives Orphan Drug Designation for the Treatment of Mitochondrial Diseases
Cyclerion Therapeutics, Inc. recently announced the US FDA has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases. Zagociguat is the first….
Cullinan Oncology Announces FDA Clearance of INDA for Novel Fusion Protein Harnessing IL-2 & IL-12 Cytokines
Cullinan Oncology, Inc. recently announced the US FDA has cleared its Investigational New Drug (IND) application for CLN-617, a fusion protein composed of two potent…
Jounce Therapeutics to be Acquired by Concentra Biosciences
Jounce Therapeutics, Inc. recently announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (Concentra) will acquire Jounce for $1.85 in cash per share plus….
Kala Pharmaceuticals Announces Positive Safety Update From Cohort 1 of Phase 2b Clinical Trial
Kala Pharmaceuticals, Inc. recently announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating…
